Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa
Yoel Lubell, Arthorn Riewpaiboon, Arjen M Dondorp, Lorenz von Seidlein, Olugbenga A Mokuolu, Margaret Nansumba, Samwel Gesase, Alison Kent, George Mtove, Rasaq Olaosebikan, Wirichada Pan Ngum, Caterina I Fanello, Ilse Hendriksen, Nicholas PJ Day, Nicholas J White & Shunmay Yeung
Volume 89, Number 7, July 2011, 504-512
Table 2. Disability weights, costs and analytical parameter values
| Parameter | Baseline estimate (distribution parameters or sensitivity analysis values) | Source |
|---|---|---|
| Mortality | ||
| Quinine (pooled) | 0.109 (β distribution; α = 167; β = 1 357) | Primary |
| Artesunate (pooled) | 0.085 (β distribution; α = 264; β = 2 847) | |
| Neurological sequelae | ||
| Quinine (pooled) | 0.012 (β distribution; α = 21; β = 2 692) | Primary |
| Artesunate (pooled) | 0.014 (β distribution; α = 22; β = 2 690) | |
| Disability weighting | ||
| Mild neurological sequelaea | 0.024 | |
| Moderate neurological sequelaeb | 0.248 | |
| Severe neurological sequelae | 0.471 | |
| Costs | ||
| Hotel (2009 US$ per day) | ||
| Ilorin, Nigeria | 18.9 | |
| Mbarara, Uganda | 7.7 | |
| Muheza, United Republic of Tanzania | 7.4 | |
| Korogwe, United Republic of Tanzania | 5.7 | |
| Quinine dihyrocholride (300 mg/ml, 2 ml ampoule) cost (US$) | 0.27 | |
| Artesunate (60 mg vial, 1 ml ampoule) cost (US$) | 1.06 | |
| Analytical values | ||
| Decision threshold (US$) | 150 (25–880) | |
| Annual discount value (%) | 3 (0–10) | |
| Age modulation | 1 (0) |
US$, United States dollar.
a Based on weighting for cognitive impairment following meningitis.
b Based on motor impairment following meningitis.